McGill 2015.
Methods | Data for participants in two phase 3 trials with linagliptin who were receiving insulin were analysed separately (n = 811) |
Participants | Type 2 diabetes mellitus participants with chronic kidney disease |
Interventions | Linagliptin + insulin vs placebo + insulin |
Outcomes | HbA1c, (severe) hypoglycaemia |
Notes | Inadequate control needs to be checked |